1-8 of 8
Edo Vellenga, MDPhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Ruth Wester, Bronno van der Holt, PhD, Emelie Asselbergs, Mark van Duin, PhD, Sonja Zweegman, MD PhD, Marie Jose Kersten, MD PhD, Edo Vellenga, MDPhD, Marinus van Marwijk Kooy, MD, Okke de Weerdt, MD, Monique Minnema, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk M. Lokhorst, MD PhD, Annemiek Broijl, MD PhD, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1141.
https://doi.org/10.1182/blood.V128.22.1141.1141
Published: 2016
Journal Articles

Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial

Pieter Sonneveld, MD PhD, Hans-Juergen Salwender, MD, Bronno Van Der Holt, PhD, Laila el Jarari, Uta Bertsch, MD, Igor W. Blau, MD, Sonja Zweegman, Katja C. Weisel, Edo Vellenga, MDPhD, Michael Pfreundschuh, Annemiek Broijl, MD PhD, Christof Scheid, MDPhD, Shulamiet Wittebol, MD, Gerard M.J. Bos, MD PhD, Marjan Stevens-Kroef, Anna Jauch, Anna Potamianou, MD PhD, Dirk Hose, MD, Reinier Raymakers, MD PhD, Marinus Schaafsme, Marie Jose Kersten, MD PhD, Marinus van Marwijk Kooy, Ulrich Duehrsen, Prof. Dr. MD, Hans Walter Lindemann, MD, Peter Brossart, MD, Pierre Wijermans, Henk M. Lokhorst, Hartmut Goldschmidt, MD
Journal: Blood
Blood (2015) 126 (23): 27.
https://doi.org/10.1182/blood.V126.23.27.27
Published: 2015
Journal Articles

Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma

Annemiek Broijl, MDPhD, Marie José Kersten, MD PhD, Wendim Ghidey Alemayehu, PhD, Mark-David Levin, MDPhD, Okke de Weerdt, MD, Edo Vellenga, MDPhD, Ellen Meijer, MDPhD, Shulamiet Wittebol, MDPhD, Rosita Ghiraw-Visser, Marian Stevens-Kroef, PhD, Berna Beverloo, PhD, Gerard M.J. Bos, MDPhD, Pierre W. Wijermans, MDPhD, Henk Lokhorst, MDPhD, Pieter Sonneveld, MDPhD
Journal: Blood
Blood (2014) 124 (21): 4735.
https://doi.org/10.1182/blood.V124.21.4735.4735
Published: 2014
Journal Articles

Establishing Human Niche Xenograft Models for Myeloid and Lymphoid Leukemia Driven By MLL-AF9

Marco Carretta, MSc, Jennifer Jaques, Bauke de Boer, MSc, Huipin Yuan, PhD, Anton C. Martens, PhD, Edo Vellenga, MDPhD, Richard W.J. Groen, PhD, Jan Jacob Schuringa, PhD
Journal: Blood
Blood (2014) 124 (21): 4781.
https://doi.org/10.1182/blood.V124.21.4781.4781
Published: 2014
Journal Articles

Erythroid Lineage Analysis By Flow Cytometry Is of Highly Additive Value for MDS Diagnosis: A Study on Behalf of the HOVON89 Study Group

Eline MP Cremers, MD, Theresia M Westers, PhD, Canan Alhan, MD, Claudia Cali, Heleen A Visser-Wisselaar, PhD, Dana A Chitu, PhD, Marian JPL Stevens-Kroef, PhD, Pedro Silva Coelho, MD, Edo Vellenga, MDPhD, Saskia K. Klein, MDPhD, Pierre W. Wijermans, MDPhD, Georgine E De Greef, Marie-Cecile Legdeur, MD PhD, Petra Muus, MD PhD, Gert J Ossenkoppele, MD PhD, Joop H Jansen, PhD, Arjan A Van de Loosdrecht, MD PhD
Journal: Blood
Blood (2014) 124 (21): 4667.
https://doi.org/10.1182/blood.V124.21.4667.4667
Published: 2014
Journal Articles

Post-Remission Treatment with Allogeneic Stem Cell Transplantation Improves Outcome in Patients Aged 60 Years and Older with Acute Myeloid Leukemia in First Remission

Jurjen Versluis, MD, Carin L.E. Hazenberg, MD, Wim van Putten, MSc, Jakob R Passweg, MD, Johan Maertens, MD PhD, Bart J Biemond, MD PhD, Harry C Schouten, MDPhD, Thomas Pabst, MD, Bob Lowenberg, MDPhD, Gert J Ossenkoppele, MDPhD, Edo Vellenga, MDPhD, Jan J Cornelissen, MD PhD
Journal: Blood
Blood (2014) 124 (21): 321.
https://doi.org/10.1182/blood.V124.21.321.321
Published: 2014
Journal Articles

The Comparative Value of Hematopoietic Stem Cell Transplantation and Chemotherapy in Cytogenetically Normal AML Subclassified By NPM1 Mutation Status and FLT3 -ITD Allelic Ratio

Jurjen Versluis, MD, Raynier Devillier, MD, Florentien in 't Hout, MD, Wim van Putten, MSc, Markus G Manz, MD, Marie-Christianne Vekemans, MD, Martyn Ronald Schaafsma, MDPhD, Jakob R Passweg, MD, Johan Maertens, MD PhD, Jurgen H Kuball, MDPhD, Leo F. Verdonck, MD PhD, Bart J Biemond, MD, Peter J.M. Valk, PhD, Marie-Joelle Mozziconacci, MD PhD, Norbert Vey, MD PhD, Harry C Schouten, MDPhD, Edo Vellenga, MDPhD, Thomas Pabst, MD, Bob Lowenberg, MDPhD, Gert J Ossenkoppele, MD PhD, Didier Blaise, MD PhD, Gerwin A Huls, MD PhD, Jan J Cornelissen, MD PhD
Journal: Blood
Blood (2014) 124 (21): 323.
https://doi.org/10.1182/blood.V124.21.323.323
Published: 2014
Journal Articles

Blinded Mid-Treatment FDG-PET in Newly Diagnosed Aggressive Non-Hodgkin Lymphoma (NHL): First Results of a Prospective Multicenter Study.

Bart W. Schot, MD, Josée Zijlstra, MD, Otto S. Hoekstra, MDPhD, Jan Pruim, MDPhD, Gustaaf W. van Imhoff, MD, Wim Sluiter, PhD, John M.M. Raemaekers, MDPhD, Wim Oyen, MDPhD, Michel Van Gelder, MDPhD, Olga Eriks, PhD, P.C. Huijgens, MDPhD, Edo Vellenga, MDPhD
Journal: Blood
Blood (2006) 108 (11): 2400.
https://doi.org/10.1182/blood.V108.11.2400.2400
Published: 2006